%0 Journal Article
%T Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
%A Hooper CY
%A Smith WJ
%J Therapeutics and Clinical Risk Management
%D 2012
%I 
%R http://dx.doi.org/10.2147/TCRM.S23247
%X vancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) Review (2283) Total Article Views Authors: Hooper CY, Smith WJ Published Date March 2012 Volume 2012:8 Pages 131 - 137 DOI: http://dx.doi.org/10.2147/TCRM.S23247 Received: 16 January 2012 Accepted: 20 February 2012 Published: 16 March 2012 Candace Y Hooper, Winter J Smith Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma Health Sciences Center College of Pharmacy, Oklahoma City, OK, USA Abstract: Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved for the treatment of complicated skin and skin-structure infections. Recently, two randomized clinical trials demonstrated the efficacy and safety of telavancin compared to vancomycin for the treatment of nosocomial pneumonia. Overall, telavancin has a favorable safety profile. However, mild gastrointestinal disturbances and reversible increases in serum creatinine were observed in clinical studies. Additional clinical studies are needed to evaluate telavancin¡¯s efficacy and safety in comparison to other antistaphylococcal agents for the treatment of infections such as bacteremia and endocarditis.
%K telavancin
%K MRSA
%K hospital-acquired pneumonia
%K health care-associated pneumonia
%K ventilator-associated pneumonia
%K nosocomial pneumonia
%U https://www.dovepress.com/telavancin-for-the-treatment-of-nosocomial-pneumonia-caused-by-methici-peer-reviewed-article-TCRM